Agbarya Abed, Sarel Ina, Ziv-Baran Tomer, Schwartz Orna, Shechtman Yelena, Kozlener Ella, Khoury Rasha, Sheikh-Ahmad Mohammad, Saiegh Leonard, Swaid Forat, Ahmad Asala Abu, Janzic Urska, Brenner Ronen
Bnai-Zion Medical Center, Oncology Institute, Haifa 3339419, Israel.
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.
Diseases. 2023 Sep 26;11(4):128. doi: 10.3390/diseases11040128.
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38-42.12), = 0.02 and 17.15 (95% CI 5.01-58.7), < 0.01, respectively). Unlike the response after two doses, the third and fourth BNT162b2 vaccine booster doses had an increased efficacy of 95-100% in cancer patients while undergoing active treatment. This result could be explained by different mechanisms including the development of memory B cells.
BNT162b2疫苗在全球范围内用于预防与COVID-19相关的发病和死亡。癌症患者由于免疫力下降而优先接种该疫苗。本研究报告了接受积极抗肿瘤治疗的癌症患者接种第三剂和第四剂疫苗后的反应率。共有142名患者接种了两剂基于mRNA的BNT162b2 COVID-19疫苗，而分别有76名和25名患者接种了三剂和四剂。两剂疫苗后体液反应的疗效在癌症患者中有所降低，尤其是在接受化疗的患者组中。在多变量分析中，与接种两剂疫苗的患者相比，接种三剂和四剂BNT162b2疫苗的患者更有可能抗体滴度处于上三分位数（优势比（OR）分别为7.62（95%CI 1.38 - 42.12），P = 0.02和17.15（95%CI 5.01 - 58.7），P < 0.01）。与两剂后的反应不同，第三剂和第四剂BNT162b2疫苗加强针在接受积极治疗的癌症患者中的疗效提高到了95% - 100%。这一结果可以通过包括记忆B细胞发育在内的不同机制来解释。
